Elevated levels of mitogen-activated protein kinase/extracellular regulatory kinase (MAPK/ERK) activity are frequently found in some cancer cells. In efforts to reduce tumor growth, attempts have been made to develop cancer therapeutic agents targeting the MAPK. Here, by use of biologic, biochemical, and gene manipulation methods in human polymorphonuclear neutrophils (PMNs), we have identified a key pathway important in normal cell function involving MAPK/ERK in PMNs for growth inhibition of Candida albicans. Contact with C albicans triggered MAPK/ERK activation in PMNs within 5 minutes, and blocking of MAPK/ERK activation, either by the pharmacologic reagent PD098059 or by dominant-negative MAPK kinase (MEK) expression via vaccinia viral delivery, suppressed antimicrobial activity. Rac and Cdc42, but not Ras or Rho, were responsible for this MAPK/ERK activation. Expression of dominant-negative Rac (N17Rac) or Cdc42 (N17Cdc42) eliminated not only C albicans- mediated ERK phosphorylation but also phagocytosis and granule migration toward the ingested microbes, whereas dominant-negative Ras (N17Ras) and Rho (N19Rho) did not. PAK1 (p21-activated kinase 1) activation is induced by C albicans, suggesting that PAK1 may also be involved in the Rac1 activation of MAPK/ERK. We conclude from these data that Rac/Cdc42-dependent activation of MAPK/ERK is a critical event in the immediate phagocytic response of PMNs to microbial challenge. Therefore, use of MAPK pharmacologic inhibitors for the treatment of cancer may result in the interruption of normal neutrophil function. A balance between therapeutic outcome and undesirable side effects must be attained to achieve successful and safe anticancer therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2001-12-0180DOI Listing

Publication Analysis

Top Keywords

mapk/erk activation
12
activation mapk/erk
8
mapk/erk
7
activation
6
human neutrophils
4
neutrophils utilize
4
utilize rac/cdc42-dependent
4
mapk
4
rac/cdc42-dependent mapk
4
mapk pathway
4

Similar Publications

Pharmacological function of melanocortin-3 receptor in goldfish (Carassius auratus).

Gen Comp Endocrinol

January 2025

College of Animal Science and Technology, Northwest A&F University, Yangling, Shaanxi 712100, China. Electronic address:

The melanocortin-3 receptor (MC3R) was recognized for its critical role in energy metabolism and inflammatory responses in mammals; however, its functions in fish remain poorly understood. This study characterized the mc3r gene in goldfish, investigating its sequence, tissue distribution, and pharmacological responses. The coding sequence of goldfish mc3r was 975 bp, translating to a 325-amino-acid protein typical of G protein-coupled receptors, with notable conservation across cyprinids.

View Article and Find Full Text PDF

Dual inhibition of MAPK/ERK and BMP signaling induces entorhinal-like identity in mouse ESC-derived pallial progenitors.

Stem Cell Reports

December 2024

Laboratorio di Biologia, Scuola Normale Superiore, 56126 Pisa, Italy; Istituto di Biofisica, Consiglio Nazionale delle Ricerche, 56124 Pisa, Italy. Electronic address:

The mechanisms that determine distinct embryonic pallial identities remain elusive. The central role of Wnt signaling in directing dorsal telencephalic progenitors to the isocortex or hippocampus has been elucidated. Here, we show that timely inhibition of MAPK/ERK and BMP signaling in neuralized mouse embryonic stem cells (ESCs) specifies a cell identity characteristic of the allocortex.

View Article and Find Full Text PDF

Background: The overall prognosis of patients with esophageal cancer (EC) is extremely poor. There is an urgent need to develop innovative therapeutic strategies. This study will investigate the anti-cancer effects of exosomes loaded with specific anti-cancer microRNAs in vivo and in vitro.

View Article and Find Full Text PDF
Article Synopsis
  • Erdheim-Chester disease (ECD) is a rare histiocytic condition often linked to mutations in the MAPK/ERK signaling pathway, with this case revealing concurrent BRAF and KRAS mutations.
  • A 70-year-old male presented with symptoms indicative of ECD, and upon genetic testing, both BRAF and KRAS mutations were identified, allowing for targeted treatment with BRAF and MEK inhibitors.
  • The combination therapy using encorafenib and binimetinib led to significant symptom relief and imaging improvements, marking the first reported use of this treatment in ECD patients.
View Article and Find Full Text PDF

Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report.

Front Oncol

December 2024

Department of Medical Oncology, International Ward, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.

Background: ROS1, a member of the sevenless subfamily of tyrosine kinase insulin receptors, promotes tumor cell survival, proliferation, and metastasis by activating the JAK/STAT, PI3K/AKT, and MAPK/ERK pathways. It only accounts for about 2% of total NSCLC cases. No cases of acquired ROS-1 rearrangement have been reported worldwide.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!